Eli Lilly and Company (LLY)
| Market Cap | 819.66B -5.1% |
| Revenue (ttm) | 65.18B +44.7% |
| Net Income | 20.64B +94.9% |
| EPS | 22.95 +96.0% |
| Shares Out | 893.36M |
| PE Ratio | 39.98 |
| Forward PE | 26.45 |
| Dividend | $6.92 (0.75%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 2,378,792 |
| Open | 914.00 |
| Previous Close | 918.05 |
| Day's Range | 910.86 - 924.53 |
| 52-Week Range | 623.78 - 1,133.95 |
| Beta | 0.43 |
| Analysts | Buy |
| Price Target | 1,182.42 (+28.87%) |
| Earnings Date | Apr 30, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for LLY stock is "Buy." The 12-month stock price target is $1,182.42, which is an increase of 28.87% from the latest price.
News
Eli Lilly's next-generation obesity drug retatrutide clears first late-stage diabetes trial
Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowe...
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%) No...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both)
Roche Holding AG has announced a major AI infrastructure expansion with Nvidia, surpassing peers in GPU deployment for drug development. RHHBY now operates over 3,500 Blackwell GPUs, positioning itsel...
Stock Of The Day: Is The Eli Lilly Selloff Over?
As you can see on the chart, in April 2025 when Eli Lilly reached the $890 level, it hit resistance. A reversal and move lower followed.
Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound's cash sales
If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.
Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations
According to Bloomberg, the downgrade (the stock's lowest on Wall Street) comes after a bit of back and forth.
4 Stocks To Buy While Everyone Else Doubts AI
Ross Gerber, CEO of Gerber Kawasaki, breaks down the 4 stocks he's buying right now — including why Micron and Nvidia are the most mispriced AI plays in the market.
Eli Lilly falls after a 6 month rally; is this a buy the dip opportunity?
Shares of Eli Lilly came under pressure on Tuesday after HSBC downgraded the stock, raising fresh questions about whether the pharmaceutical giant's strong run in the obesity drug market can continue ...
Eli Lilly Stock Gets Downgraded. It Faces Stiff Headwinds After Strong Run-Up.
Eli Lilly, the maker of Zepbound and Mounjaro, faces stiff price competition in the coming year, HSBC says.
Tuesday's Morning Movers: DAL Lifts Guidance, LLY & DKNG Downgrades
Delta Airlines (DAL) upped its revenue guidance to high single-digit growth, giving a much-needed boost to shares after airlines took a hit over Iran uncertainty. HSBC shed bullish optimism in Eli Lil...
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16 In key secondary endpoints, 39% of pati...
Invesco Rising Dividends Fund Q4 2025 Portfolio Activity
Linde was purchased due to its essential and resilient business model, anchored by long-term contracts and leadership in industrial gases. We sold Oracle due to concerns about downside risk as its inv...
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
Eli Lilly and Co (NYSE: LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12.
Eli Lilly: The Weight-Loss Craze Isn't Over
Eli Lilly is rated a strong buy with a $1,623 price target, driven by multiple near- and long-term catalysts. Orforglipron's Q2 launch and Medicare/Medicaid eligibility will expand LLY's addressable m...
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
British drugmaker AstraZeneca Plc (NYSE: AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ: ABVX), following the company's dramatic valuation surge after strong cli...
Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks
Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lilly's Zepbound could present health risks to consumers due to a previously unidentified impurity caused in the p...
India warns drugmakers against direct or surrogate weight-loss drug and obesity ads
India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could act as surrogate promotion...
Goldman Sachs Large Cap Equity Fund Q4 2025 Portfolio Activity
Our position in American pharmaceutical company, Eli Lilly & Company (1.8%), was a top contributor to relative returns during the fourth quarter. Our position in global semiconductor company, Advanced...
Harbor Health Care ETF Q4 2025 Portfolio Review
Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly deliv...
Health Rounds: Death from dementia on the rise among people with type 2 diabetes
In people with type 2 diabetes in the world's richest countries, deaths from cardiovascular disease are declining while mortality from dementia is on the rise, a large analysis has found.
Eli Lilly to invest $3 billion in China over next decade
Eli Lilly plans to invest $3 billion over the next decade to expand supply chain capacity in China and build production capacity for type-2 diabetes and obesity treatment orforglipron, the phar...
Is Lilly Stock Still The Best Growth Story In Healthcare?
Eli Lilly's stock has not performed as well as some significant competitors over the past year, though its noteworthy growth in areas such as GLP-1 therapies is still impressive. A detailed examinatio...
Virtus Large Cap Growth SMA Q4 2025 Portfolio Review
The Silvant Large Cap Growth SMA returned +2.69% (gross)/+1.94% (net) for the quarter, outperforming the Russell 1000 Growth Index's return of +1.12%. Eli Lilly and Alphabet were among the top stock c...